ArticleHealth science reports2025
The Role of Cardiac Resynchronization Therapy in Heart Failure: A Narrative Review.
Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Structural and functional cardiac defects leading to inadequate tissue oxygenation is known as Heart failure (HF) which is characterized by extensive morbidity and mortality. Pathophysiology of HF involves systolic and diastolic dysfunction, neurohormonal dysregulation, and imbalance in inflammatory mediators which complicates treatment further. Cardiac resynchronization therapy (CRT) is an approach used for restoring ventricular synchrony and enhancing mechanical efficiency. This study discusses various key points of CRT and its uses in HF and discusses challenges and future implications. Methods: An extensive review of the literature was conducted with evidence from several databases like Medline, PubMed Central, and Embase. Preference was given to articles published after 2010, but relevant articles even pre-2010 were included. Mendeley was used as a reference manager for formatting. Results: Functional improvements and an enhanced quality of life across a diverse range of patients have been demonstrated using CRT. This has significantly impacted the mortality rates of patients with HF. This manuscript conducted a comparative analysis various hallmark clinical trials conducted in lieu of CRT, across many years (2002, 2003, 2004, 2005, 2017, 2018, 2020). All trials have noted the supremacy of CRT compared to pharmaceutical treatment or other therapeutic methods. Majority of the trial participants had an LVEF of ≤ 35%, a QRS duration of ≤ 150 ms, and were categorized as NYHA class II-IV before initiation of CRT and, posttreatment, LVEF was improved significantly. The main advantages noted were functional improvements, such as enhanced quality of life and reduced mortality. Conclusion: There have been multiple efforts undertaken to address the challenges in CRT, which include a reduction in the rates of nonresponding patients and using alternative adjunctive therapies like defibrillators. These have been shown to improve outcomes among HF patients. Although CRT is noted to be very efficient, some challenges like technological limitations, uncertainty regarding optimal pacing, and nonresponding patients, exist. Ongoing research aims to further develop and revolutionize HF care and improve patient outcomes across the world by refining patient selections and CRT efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.